Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients

Leukemia and Lymphoma

Volumn 51, Issue 10, 2010, Pages 1779-1792

  Rourke, Meghan ^a   Anderson, Kenneth C ^a   Ghobrial, Irene M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

chemotherapeutic approaches; Lymphoma and Hodgkin disease; prognostication

Indexed keywords

ALEMTUZUMAB; ATACICEPT; BORTEZOMIB; CARFILZOMIB; CARMUSTINE; CEFOTAXIME; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; EVEROLIMUS; FLUDARABINE; IMATINIB; IMMUNOGLOBULIN M; LENALIDOMIDE; MELPHALAN; OBLIMERSEN; PENTOSTATIN; PERIFOSINE; PREDNISONE; RITUXIMAB; SILDENAFIL; THALIDOMIDE; VINCRISTINE; VINCRISTINE SULFATE;

COCHRANE LIBRARY; DISEASE FREE SURVIVAL; DRUG RESPONSE; EVENT FREE SURVIVAL; HUMAN; MEDLINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUBLISHING; RELAPSE; REVIEW; SURVIVAL; SYSTEMATIC REVIEW; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CHLORAMBUCIL; CLADRIBINE; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; TREATMENT OUTCOME; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 77957727618     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.499977     Document Type: Review

References (72)

1. Dimopoulos MA, Alexanian R. Waldenstrom's macroglobu-linemia. Blood 1994;83:1452-1459.
2. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macro-globulinaemia. Lancet Oncol 2003;4:679-685.
3. Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood 2007;109:5096-5103.
4. Treon SP. How I treat Waldenstrom's macroglobulinemia. Blood 2009;114:2375-2385.
5. Waldenstrom J. Incipient myelomatosis or 'essential' hyper-globulinemia with fibrinogenopenia-a new syndrome? Acta Med Scand 1944;117:216-247.
6. Treon SP, Dimopoulos M, Kyle RA. Defining Waldenstrom's macroglobulinemia. Semin Oncol 2003;30:107-109.
7. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
8. Herrinton L, Weiss NS. Incidence ofWaldenstrom's macro-globulinemia. Blood 1993;82:3148-3150.
9. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Work-shop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110-115.
10. Remstein ED, Hanson CA, Kyle RA, Hodnefield JM, Kurtin PJ. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consis-tently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Semin Oncol 2003;30:182-186.
11. Hunter Z, Branagan AR, Manning R, et al. CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005;5:246-249.
12. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom's macroglobuli-nemia. J Clin Oncol 2005;23:1564-1577.
13. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006;133:158-164.
14. Ghobrial IM, Witzig TE. Waldenstrom macroglobulinemia. Curr Treat Options Oncol 2004;5:239-247.
15. Vijay A, Gertz MA. Current treatment options for Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma 2008;8:219-229.
16. Schnitzler L, Schubert B, Boasson M, Gardais J, Tourmen A. Urticaire chronique, lésions osseuses, macroglobulinémie IgM: maladie de Waldenstrom? Bull Soc Fr Derm Syph 1974;81:363-367.
17. Gertz M, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglobulinemia. 1993;11:914-920.
18. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom's macroglobulinemia. Blood 2009;113:4163-4170.
19. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 2006;107:3442-3446.
20. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobu-linemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobuline-mia. Semin Oncol 2003;30:116-120.
21. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2008;27:120-126.
22. Kyle RA, Greipp PR, Gertz MA, et al. Waldenstrom's macro-globulinaemia: a prospective study comparing daily with inter-mittent oral chlorambucil. Br J Haematol 2000;108:737-742.
23. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993;11:1553-1558.
24. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med 1993;95:49-52.
25. Leblond V, Ben-Othman T, Deconinck E, et al. Activity of fludarabine in previously treated Waldenstrom's macroglobu-linemia: a report of 71 cases. Groupe Cooperatif Macro-globulinemie. J Clin Oncol 1998;16:2060-2064.
26. Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US inter-group trial (SW0G S9003). Semin Oncol 2003;30:220-225.
27. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macro-globulinemia. Semin Oncol 2003;30:243-247.
28. Dimopoulos MA, Kantarjian H, Estey E, et al. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadeno-sine. Ann Intern Med 1993;118:195-198.
29. Gertz MA, Abonour R, Heffner LT, Greipp PR, Uno H, Rajkumar SV. Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol 2009;147:677-680.
30. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047-2055. (Pubitemid 39232853)
31. Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituxi-mab therapy for previously untreated patients with Walden-strom's macroglobulinemia. Clin Lymphoma 2002;3:163-166.
32. Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 2005;16:132-138.
33. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Cas-tritis E, Bitsaktsis A, Pangalis GA. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezo-mib. Haematologica 2005;90:1655-1658.
34. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macro-globulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570-1575.
35. Treon S, Hunter Z, Matous J, et al. Phase II study of bortezomib in Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Blood 2005;106(Suppl. 1): (Abstract).
36. Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1408-1414.
37. Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Walden-strom's macroglobulinemia. Clin Cancer Res 2010;16:1033-1041.
38. Leblond V, Levy V, Maloisel F, et al. Multicenter, randomized comparative trial of fludarabine and the combi-nation of cyclophosphamide-doxorubicin- prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 2001;98:2640-2644.
39. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dex-amethasone, and rituximab: WMCTG Clinical Trial 05-180. J Clin Oncol 2009;15:355-360.
40. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009;15:355-360.
41. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112:4452-4457.
42. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1422-1428.
43. Hunter Z, Boxer M, Kahl B, Patterson CJ, Soumerai JD, Treon SP. Phase II study of alemtuzumab in lymphoplasma-cytic lymphoma: results of WMCTG trial 02-079. J Clin Oncol 2006;24(Suppl.): Abstract 427.
44. Ghobrial I, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom's macroglobulinemia. Blood 2009;114(Suppl.): (Abstract 3752).
45. Weber D, Treon SP, Emmanouilides C, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: con-sensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:127-131.
46. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobuline-mia. Clin Lymphoma Myeloma 2006;6:380-383.
47. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9.
48. Treon SP, Branagan AR, Ioakimidis L, et al. Long term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2008;113:3673-3678.
49. Leleu X, Moreau AS, Weller E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma 2008;49:1104-1107.
50. Katzmann JA, Abraham RS, Dispenzieri A, LustJA, Kyle RA. Diagnostic performance ofquantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005; 51:878-881.
51. Dimopoulos MA, Kantarjian H, Weber D, et al. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994;12:2694-2698.
52. Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenstrom's macroglobuline-mia resistant to standard therapy with 2-chlorodeoxyadeno-sine: identification of prognostic factors. Ann Oncol 1995; 6:49-52.
53. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327-2333.
54. Dimopoulos MA, Tsatalas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003;30: 265-269.
55. Rossi JF, Moreaux J, Hose D, et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macro-globulinemia: a phase I study. Br J Cancer 2009;101:1051-1058.
56. Tam CS, Wolf MM, Westerman D, Januszewicz EH, Prince HM, Seymour JF. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myelo-ma 2005;6:136-139.
57. Leblond V, Tamburini J, Levy V, et al. Treatment of Waldenström's macroglobulinemia with the combination of fludarabine and cyclophosphamide: results in 49 patients. Leukemia 2005;10:1831-1834.
58. Dimopoulos MA, Hamilos G, Efstathiou E, et al. Treatment ofWaldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma 2003; 44:993-996.
59. Tam CS, WolfM, Prince HM, et al. Fludarabine, cyclopho-sphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006;106:2412-2420.
60. Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglo-bulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 2005;6:131-135.
61. Petrucci M, Avvisati G, Tribalto M, Giovangrossi P, Mandelli F. Waldenstrom's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients. J Intern Med 1989;226:443-447.
62. Case DJ, Ervin TJ, Boyd MA, Redfield DL. Waldenstrom's macroglobulinemia: long-term results with the M-2 protocol. Cancer 1991;9:1-7.
63. Annibali O, Petrucci MT, Martini V, et al. Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis. Cancer 2005;103:582-587.
64. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25:3344-3349.
65. Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lympho-ma 2005;5:273-277.
66. Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009;23:153-161.
67. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom's macroglobulinemia. Blood 2008;15:355-360.
68. Gertz MA, Geyer SM, Badros A, Kahl BS, Erlichman C. Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lympho-ma 2005;5:282-284.
69. Patterson C, Soumerai J, Hunter Z, Leleu X, Ghobrial I, Treon SP. Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia. J Clin Oncol 2006;24(Suppl.): Abstract 435S.
70. Treon S, Jacob S, Patterson C, et al. Imatinib mesylate (Gleevec) is active in relapsed/refractory Waldenstrom's macroglobulinemia: planned interim results of WMCTG Clinical Trial 05-140. Blood 2006;108(Suppl. 1): (Abstract 2484).
71. Ghobrial I, Harousseau JL, Treon SP, Wooldridge J, Leblond V. Enzastaurin in previously treated Waldenstrom's macro-globulinemia: an open-label, multicenter, phase II study. Blood 2009;114(Suppl. 1): (Abstract3867).
72. O'Connor O, Stewart AK, Vallone M, et al. A Phase I Dose Escalation Study of the Safety and Pharmacokinetics ofthe Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies. 2009;15:7085-7091.